An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Acute Exposure Guideline Levels for Selected Airborne Chemicals: Volume 15.
Committee on Acute Exposure Guideline Levels; Committee on Toxicology; Board on Environmental Studies and Toxicology; Division on Earth and Life Studies; National Reserch Council.
Washington (DC): National Academies Press (US); 2013 Sep 26.
Top results in this bookTable of Contents
Clinical Review Report: Cysteamine 3.8 mg/mL ophthalmic solution (Cystadrops): (Recordati Rare Diseases Canada Inc.): Indication: Treatment of corneal cystine crystal deposits in adults and children from two years of age with cystinosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.
NTP Technical Report on the Toxicity Studies of Sodium Thioglycolate (CASRN 367-51-1) Administered Dermally to F344/N Rats and B6C3F1/N Mice: Toxicity Report 80 [Internet].
National Toxicology Program.
Research Triangle Park (NC): National Toxicology Program; 2016 May.
Clinical Review Report: Cysteamine delayed-release capsules (Procysbi): Horizon Pharma Ireland Ltd. Indication: For the treatment of nephropathic cystinosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb.
Toxicological Profile for Methyl Mercaptan.
Atlanta (GA): Agency for Toxic Substances and Disease Registry (US); 1992 Sep.
Pharmacoeconomic Review Report: Cysteamine delayed-release capsules (Procysbi): Horizon Pharma Ireland Ltd. Indication: For the treatment of nephropathic cystinosis [Internet].
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Pharmacoeconomic Review Report: Cysteamine 3.8 mg/mL Ophthalmic Solution (Cystadrops): (Recordati Rare Diseases Canada Inc.): Indication: Treatment of corneal cystine crystal deposits in adults and children from two years of age with cystinosis [Internet].
Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
Assay Guidance Manual [Internet].
Markossian S, Grossman A, Arkin M, et al., editors.
Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
Lyon (FR): International Agency for Research on Cancer; 1999. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 71.)
Arsenic: Medical and Biologic Effects of Environmental Pollutants.
National Research Council (US) Committee on Medical and Biological Effects of Environmental Pollutants.
Washington (DC): National Academies Press (US); 1977.
Probe Reports from the NIH Molecular Libraries Program [Internet].
Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
Conference on Hemoglobin: 2–3 May 1957.
National Academy of Sciences (US) and National Research Council (US) Division of Medical Sciences.
Washington (DC): National Academies Press (US); 1958.
Fifteenth Interim Report of the Committee on Acute Exposure Guideline Levels.
National Research Council (US) Committee on Acute Exposure Guideline Levels; National Research Council (US) Committee on Toxicology.
Washington (DC): National Academies Press (US); 2008.
Madame Curie Bioscience Database [Internet].
Austin (TX): Landes Bioscience; 2000-2013.
CADTH Canadian Drug Expert Committee Recommendation: Cysteamine Delayed-Release (Procysbi — Horizon Pharma Ireland Ltd.): Indication: Nephropathic cystinosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan.
Nineteenth Interim Report of the Committee on Acute Exposure Guideline Levels: Part A.
Washington (DC): National Academies Press (US); 2011.
CADTH Canadian Drug Expert Committee Recommendation: Cysteamine Ophthalmic Solution (Cystadrops — Recordati Rare Diseases Canada Inc.): Indication: Treatment of corneal cystine crystal deposits (CCCDs) in adults and children from 2 years of age with cystinosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.
Drinking Water and Health: Volume 2.
National Research Council (US) Safe Drinking Water Committee.
Washington (DC): National Academies Press (US); 1980.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on